Regulatory
Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated
Shots: The US FDA approval is based on clinical safety and efficacy data of Recarbrio (injection, 1.25gm) approved for cUTI including pyelonephritis, caused by certain Gram-negative microorganism and also indicated […]readmore